ACA
IONS icon

American Capital Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

American Capital Advisory’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$476 Sell
6
-1
-14% -$75 ﹤0.01% 961
2026
Q1 		$526 Buy
7
+5
+250% +$395 ﹤0.01% 844
2025
Q4 		$159 Hold
2
– – ﹤0.01% 939
2025
Q3 		$131 Buy
+2
New +$98 ﹤0.01% 933

Other funds holding IONS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

American Capital Advisory's IONS Position: Q2 2026 in Review

American Capital Advisory reduced its Ionis Pharmaceuticals (IONS) stake by 14% in Q2 2026, selling an estimated $75 and leaving 6 shares worth $476. The position accounts for ﹤0.01% of the portfolio, ranked #961.

American Capital Advisory first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $526 in Q1 2026. 220 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • American Capital Advisory held 6 shares of Ionis Pharmaceuticals worth $476 as of Q2 2026.
  • American Capital Advisory sold 1 Ionis Pharmaceuticals share in Q2 2026, an estimated $75.
  • Ionis Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #961 holding.
  • American Capital Advisory first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • American Capital Advisory's Ionis Pharmaceuticals position peaked at $526 in Q1 2026.
  • 220 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.